News & Updates
Showing Multidisciplinary articles
Showing

TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
29 Feb 2024
Adjuvant pembrolizumab holds promise in bladder cancer
The phase III AMBASSADOR Alliance A031501 trial showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS) with adjuvant pembrolizumab compared with observation in patients with high-risk locally advanced muscle-invasive urothelial carcinoma (MIUC) after radical surgery regardless of PD-L1 status.







